Late mortality in people with cancer: a population-based Australian study
- PMID: 33296507
- DOI: 10.5694/mja2.50879
Late mortality in people with cancer: a population-based Australian study
Abstract
Objectives: To investigate causes of death of people with cancer alive five years after diagnosis, and to compare mortality rates for this group with those of the general population.
Design, setting, participants: Retrospective cohort study; analysis of South Australian Cancer Registry data for all people diagnosed with cancer during 1990-1999 and alive five years after diagnosis, with follow-up to 31 December 2016.
Main outcome measures: All-cause and cancer cause-specific mortality, by cancer diagnosis; standardised mortality ratios (study group v SA general population) by sex, age at diagnosis, follow-up period, and index cancer.
Results: Of 32 646 people with cancer alive five years after diagnosis, 30 309 were of European background (93%) and 16 400 were males (50%); the mean age at diagnosis was 60.3 years (SD, 15.7 years). The median follow-up time was 17 years (IQR, 11-21 years); 17 268 deaths were recorded (53% of patients; mean age, 80.6 years; SD, 11.4 years): 7845 attributed to cancer (45% of deaths) and 9423 attributed to non-cancer causes (55%). Ischaemic heart disease was the leading cause of death (2393 deaths), followed by prostate cancer (1424), cerebrovascular disease (1175), and breast cancer (1118). The overall standardised mortality ratio (adjusted for age, sex, and year of diagnosis) was 1.24 (95% CI, 1.22-1.25). The cumulative number of cardiovascular deaths exceeded that of cancer cause-specific deaths from 13 years after cancer diagnosis.
Conclusions: Mortality among people with cancer who are alive at least five years after diagnosis was higher than for the general population, particularly cardiovascular disease-related mortality. Survivorship care should include early recognition and management of risk factors for cardiovascular disease.
Keywords: Cancer; Mortality.
© 2020 AMPCo Pty Ltd.
Comment in
-
Evidence-based care to support longer, healthier lives for cancer survivors.Med J Aust. 2021 Apr;214(7):308-309. doi: 10.5694/mja2.50995. Epub 2021 Mar 27. Med J Aust. 2021. PMID: 33774824 No abstract available.
Similar articles
-
A population-based study of cardiovascular disease mortality risk in US cancer patients.Eur Heart J. 2019 Dec 21;40(48):3889-3897. doi: 10.1093/eurheartj/ehz766. Eur Heart J. 2019. PMID: 31761945 Free PMC article.
-
A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer.JAMA Cardiol. 2017 Jan 1;2(1):88-93. doi: 10.1001/jamacardio.2016.3841. JAMA Cardiol. 2017. PMID: 27732702
-
Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women.Thyroid. 2017 Aug;27(8):1001-1010. doi: 10.1089/thy.2017.0063. Epub 2017 Jul 6. Thyroid. 2017. PMID: 28578598 Free PMC article.
-
Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.Dan Med J. 2018 Apr;65(4):B5454. Dan Med J. 2018. PMID: 29619932 Review.
-
Cardiovascular disease at the turn of the century.Med J Aust. 1999 May 3;170(9):408-9. doi: 10.5694/j.1326-5377.1999.tb127813.x. Med J Aust. 1999. PMID: 10341770 Review. No abstract available.
Cited by
-
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study.Lancet Reg Health West Pac. 2023 Aug 2;39:100872. doi: 10.1016/j.lanwpc.2023.100872. eCollection 2023 Oct. Lancet Reg Health West Pac. 2023. PMID: 37565067 Free PMC article.
-
Text message intervention delivered from Australian general practices to improve breast cancer survivors' physical activity and cardiovascular risk factors: protocol for the EMPOWER-SMS-GP effectiveness implementation randomised controlled trial.BMJ Open. 2024 Dec 11;14(12):e090984. doi: 10.1136/bmjopen-2024-090984. BMJ Open. 2024. PMID: 39663171 Free PMC article.
-
Breast and prostate cancer survivors' understanding of risk and management of cardiovascular and musculoskeletal side effects of treatment: findings from focus groups.Support Care Cancer. 2025 Jun 21;33(7):608. doi: 10.1007/s00520-025-09642-z. Support Care Cancer. 2025. PMID: 40542843 Free PMC article.
-
Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer.Cancers (Basel). 2023 Feb 8;15(4):1094. doi: 10.3390/cancers15041094. Cancers (Basel). 2023. PMID: 36831436 Free PMC article.
-
Radiation-induced cardiac side-effects: The lung as target for interacting damage and intervention.Front Oncol. 2022 Jul 22;12:931023. doi: 10.3389/fonc.2022.931023. eCollection 2022. Front Oncol. 2022. PMID: 35936724 Free PMC article. Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
-
- Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol 2014; 32: 2662-2668.
-
- Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 2011; 7: 371-374.
-
- Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin 2016; 66: 337-350.
-
- Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-1314.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical